Patient Support Programs (PSPs) are embedded in the Canadian pharmaceutical landscape and have become a critical component of commercialization strategies. Yet as financial pressures intensify, commercial and brand leaders need to be able to identify, measure and communicate the value they bring.

This session will explore the evolution of PSPs in Canada and ways in which to better connect PSP investments to patient outcomes, brand performance, market access, and long-term commercial success.